Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

This study has been completed.
Phoenix International Life Sciences, Inc.
Information provided by:
Par Pharmaceutical, Inc. Identifier:
First received: April 1, 2008
Last updated: NA
Last verified: April 2008
History: No changes posted
To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Condition Intervention Phase
To Determine Bioequivalence Under Fasting Conditions
Drug: buspirone HCl
Drug: Buspar
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose

Resource links provided by NLM:

Further study details as provided by Par Pharmaceutical, Inc.:

Primary Outcome Measures:
  • Rate and extent of absorption [ Time Frame: 24 hours ]

Enrollment: 48
Study Start Date: June 1998
Study Completion Date: September 1998
Primary Completion Date: September 1998 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
Drug: buspirone HCl
Tablets, 30 mg, single-dose
Other Name: Buspar
Active Comparator: B
Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
Drug: Buspar
Tablets, 30 mg, single-dose
Other Name: buspirone HCl

Detailed Description:
To compare the single-dose bioavailability of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets under fasting conditions, following administration of a 30 mg dose

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers, 18-45 years of age
  • Weighing at least 60 kg, who are within 10% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983)
  • Physical examination and laboratory tests of hematologic, hepatic and renal functions
  • Medically healthy subjects with clinically normal laboratory profiles will be enrolled in the study

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease
  • The presence of alcoholism or drug abuse within the past year
  • Hypersensitivity or idiosyncratic reaction to buspirone HCl
  • Subjects who have been receiving monoamine oxidase inhibitors
  • Subjects who have been on an abnormal diet (for whatever reason) during the 28 days preceding the study
  • Subjects who, through completion of the study, would have donated in excess of 500 mL blood in 14 days, or 500-750 mL of blood in 14 days (unless approved by Principal Investigator, 1000 mL blood in 90 days, 1250 mL blood in 120 days, 1500 mL blood in 180 days, 2000 mL blood in 270 days, 2500 mL blood in 1 year
  • Subjects who have participated in another clinical trial within 28 days of study start
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00653419

Canada, Quebec
Phoenix International Life Sciences, Inc.
St-Laurent, Quebec, Canada, H4R 2N6
Sponsors and Collaborators
Par Pharmaceutical, Inc.
Phoenix International Life Sciences, Inc.
Principal Investigator: Samuel Serfaty, MD Phoenix International Life Sciences, Inc.
  More Information

Responsible Party: Alfred Elvin/Director of Biopharmaceutics, Par Pharmaceutical Inc. Identifier: NCT00653419     History of Changes
Other Study ID Numbers: 980563
Study First Received: April 1, 2008
Last Updated: April 1, 2008

Keywords provided by Par Pharmaceutical, Inc.:
buspirone HCl

Additional relevant MeSH terms:
Pathologic Processes
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017